Search & Analyze

Neuland Laboratories Ltd.

HealthcarePharmaceuticals & Drugs

www.neulandlabs.com BSE: 524558NSE: NEULANDLAB

₹22,702.65BSE0.13%

16 Sep, 4:01 PM

₹22,702.65

₹29.06K Cr

58.39

14.38

21.43%

₹23,115.00

₹21,858.35

₹24,235.05

₹11,500.00

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,853.50	36.77	4,44,716.74	0.86	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,199.70	83.50	2,44,223.13	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,823.05	84.11	1,83,453.32	0.79	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,105.00	24.42	1,10,224.17	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,359.75	32.59	1,09,848.55	0.96	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,906.00	94.19	1,02,983.51	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,145.25	29.67	95,591.76	0.70	435.60	-69.10%	8,099.80	-5.51%	13.75
Neuland Laboratories Ltd. NEULANDLAB	22,702.65	58.39	29,063.68	0.15	147.67	962.40%	641.58	119.15%	27.50

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	385.01	439.60	310.84	398.03	328.36	292.75	514.27	439.71	776.25	641.58
Expenses	278.09	316.24	248.62	311.43	277.29	258.26	358.73	362.58	468.92	418.69
	106.92	123.36	62.23	86.60	51.07	34.49	155.55	77.13	307.33	222.89
	27.77%	28.06%	20.02%	21.76%	15.55%	11.78%	30.25%	17.54%	39.59%	34.74%
	5.36	25.43	4.33	59.68	7.46	7.86	1.80	8.05	12.46	8.49
Interest	3.61	2.67	1.06	2.22	2.35	4.59	5.37	6.79	7.21	6.97
	16.46	16.28	16.07	16.30	16.89	20.19	22.54	23.92	25.09	26.56
	92.20	129.84	49.42	127.76	39.30	17.57	129.44	54.48	287.50	197.85
	26.72%	24.62%	33.55%	20.49%	29.25%	20.89%	25.17%	25.52%	26.03%	25.36%
	67.56	97.87	32.84	101.59	27.81	13.90	96.85	40.57	212.67	147.67
	52.37	75.86	25.46	78.75	21.56	10.78	75.07	31.45	164.86	114.48

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	951.08	1,191.20	1,558.58	1,476.84	2,022.99
	951.08	1,191.20	1,558.58	1,476.84	2,022.99
EXPENDITURE :
Increase/Decrease in Stock	-15.41	-9.51	-55.14	12.83	-64.26
Raw Material Consumed	437.55	487.74	632.43	574.81	819.76
Power & Fuel Cost	42.21	48.62	48.72	50.56	58.14
Employee Cost	182.47	201.79	257.06	272.00	341.14
Other Manufacturing Expenses	89.16	86.94	107.79	112.31	133.47
General and Administration Expenses	35.80	51.22	60.91	84.81	109.39
Selling and Distribution Expenses	27.40	29.58	33.94	23.83	30.90
Miscellaneous Expenses	9.28	22.99	10.29	22.42	19.94
	808.46	919.36	1,095.99	1,153.58	1,448.49
Operating Profit (Excl OI)	142.62	271.84	462.59	323.26	574.50
	2.08	9.75	12.54	20.51	30.17
	144.70	281.59	475.13	343.77	604.66
Interest	13.50	13.07	14.00	8.30	23.95
PBDT	131.20	268.52	461.14	335.47	580.72
	49.04	52.78	59.70	65.55	91.74
Profit Before Taxation & Exceptional Items	82.16	215.75	401.44	269.93	488.98
Exceptional Income / Expenses				76.40
	82.16	215.75	401.44	346.33	488.98
Provision for Tax	18.34	52.23	101.36	86.22	124.98
	63.82	163.52	300.08	260.11	364.00
Extra items			0.00	0.00	0.00
Consolidated Net Profit	63.82	163.52	300.08	260.11	364.00
Profit Balance B/F	248.16	308.13	465.23	752.48	994.63
Appropriations	311.98	471.65	765.31	1,012.59	1,358.63
Equity Dividend %	50.00%	100.00%	140.00%	120.00%	340.00%
	49.74	127.45	233.89	202.74	283.71
Adjusted EPS	49.74	127.45	233.89	202.74	283.71

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	12.90	12.90	12.90	12.90	12.90
Total Reserves	827.60	981.20	1,269.80	1,511.91	1,861.57
Reserve excluding Revaluation Reserve	826.76	980.36	1,268.97	1,511.07	1,860.73
Revaluation reserve	0.84	0.84	0.84	0.84	0.84
	840.50	994.10	1,282.70	1,524.81	1,874.47
Secured Loans	104.25	74.25	44.92	90.73	160.95
Deferred Tax Assets / Liabilities	56.70	58.30	60.44	72.82	68.96
Other Long Term Liabilities	6.97	3.88	9.20	18.62	99.69
Long Term Provisions	11.91	10.29	7.61	7.22	15.86
Total Non-Current Liabilities	179.83	146.71	122.17	189.39	345.47
Trade Payables	117.38	171.01	191.96	252.20	269.14
Other Current Liabilities	152.35	244.87	234.01	211.30	420.59
Short Term Borrowings	92.21	11.16
Short Term Provisions	1.21	11.93	1.72	2.19	20.46
Total Current Liabilities	363.16	438.96	427.68	465.69	710.20
Total Liabilities	1,383.49	1,579.76	1,832.56	2,179.88	2,930.14
Gross Block	913.27	950.36	1,069.76	1,233.31	1,531.51
Less: Accumulated Depreciation	165.57	212.17	265.12	278.40	354.58
Net Block	747.70	738.19	804.64	954.92	1,176.93
Capital Work in Progress	20.46	40.57	45.89	44.55	209.50
Non Current Investments	0.50	0.52	1.28	1.53	1.98
Long Term Investment	0.50	0.52	1.28	1.53	1.98
Long Term Loans & Advances	14.38	20.24	40.47	36.04	57.36
Other Non Current Assets			0.17	0.23	0.16
Total Non-Current Assets	802.70	818.87	911.48	1,040.38	1,447.01
Currents Investments	3.38			107.68
Inventories	265.21	279.23	350.42	385.76	510.29
Sundry Debtors	234.33	361.77	373.53	315.72	541.35
Cash and Bank	20.36	59.10	116.80	258.82	354.96
Other Current Assets	11.52	13.70	18.30	19.70	24.55
Short Term Loans and Advances	46.00	47.09	62.03	51.82	51.98
Total Current Assets	580.79	760.89	921.08	1,139.50	1,483.13
Net Current Assets (Including Current Investments)	217.64	321.94	493.40	673.81	772.93
Total Assets	1,383.49	1,579.76	1,832.56	2,179.88	2,930.14
Contingent Liabilities	74.68	91.21	27.73	8.97	13.18
Total Debt	230.95	121.51	82.51	136.01	196.61
	654.40	774.12	999.07	1,187.77	1,460.31
Adjusted Book Value	654.40	774.12	999.07	1,187.77	1,460.31

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	82.16	215.75	401.44	346.33	488.98
Adjustment	66.30	77.93	62.08	-11.98	102.65
Changes In working Capital	-67.58	-12.83	-90.73	57.78	-141.42
Cash Flow after changes in Working Capital	80.88	280.84	372.78	392.13	450.21
Cash Flow from Operating Activities	60.39	237.21	261.18	317.40	346.68
Cash Flow from Investing Activities	-95.52	-61.50	-149.69	-298.16	-423.73
Cash Flow from Financing Activitie	37.72	-135.80	-69.28	24.96	20.98
Net Cash Inflow / Outflow	2.59	39.92	42.21	44.21	-56.08
Opening Cash & Cash Equivalents	2.44	5.09	45.42	87.58	131.93
Effect of Foreign Exchange Fluctuations	0.06	0.41	-0.05	0.15	0.82
Closing Cash & Cash Equivalent	5.09	45.42	87.58	131.93	76.67

Ratios

Valuation

58.39

14.38

36.42

12.25

387.98

1,575.41

Profitability

21.43

27.50

14.25

28.40

17.99

Leverage & Liquidity

0.10

2.09

21.42

Returns

0.15

0.79

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	32.72	32.64	32.68	32.68	32.68	32.64	32.63	32.63	32.62
	32.51	33.24	33.35	33.48	33.66	34.54	35.61	36.30	37.59
	34.76	34.11	33.97	33.84	33.67	32.81	31.76	31.07	29.79
	67.28	67.36	67.32	67.32	67.32	67.36	67.37	67.37	67.38
No. of Shareholders	29,077	34,567	39,315	39,333	42,419	44,393	46,187	46,304	44,340

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-07-20	Board Meeting	Quarterly Results
2026-05-12	Ex Dividend	Rs.34.0000 per share(340%)Final Dividend	2026-07-24	2026-07-24
2026-05-12	AGM

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Neuland Laboratories Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

10 members across the board and senior leadership

Sarada Bhamidipati

Company Secretary & Compliance Officer

—

Davuluri Rama Mohan Rao

Chairman

₹14.67 Cr

Mar '26

Davuluri Sucheth Rao

Vice Chairman

₹13.80 Cr

Mar '26

Davuluri Saharsh Rao

Managing Director & Chief Executive Officer

₹13.80 Cr

Mar '26

Homi Rustam Khusrokhan